151751-Najiba-Chargi

187 Systemic therapy: skeletal muscle mass and chemoradiotherapy Table 2. Anthropometric and clinical measurements according to SMM status and DLT status Total N=343 Mean, SD Without low SMM n=144 41.98% Mean, SD With Low SMM n=199 58.01% Mean, SD p Without DLT n=189 55.1% Mean, SD With DLT n=154 44.9% Mean, SD p Weight ( kg) 73.5 (16.1) 82.3 (15.7) 67.2 (13.2) <0.01 74.6 (16.4) 72.3 (15.7) 0.17 Length (m) 1.7 (0.1) 1.8 (0.1) 1.7 (0.1) <0.01 1.8 (0.1) 1.7 (0.1) 0.82 BMI (n, %) 18.5-24.9 kg/m 2 191 (55.7) 61 (31.9) 130 (68.1) <0.01 99 (51.8) 92 (48.2) 0.03 <18.5 kg/m 2 30 (8.7) 0 30 (100) 12 (40) 18 (60) 25-29.9 kg/m 2 84 (24.5) 55 (65.5) 29 (34.5) 57 (67.9) 27 (32.1) ≥30 kg/m 2 38 (11.1) 28 (73.7) 10 (26.3) 21 (55.3) 17 (44.7) Body surface area (m 2 ) Median (IQR) 1.9 (1.7-2.0) 2.0 (0.2) 1.79 (0.2) <0.01 1.89 (0.2) 1.86 (0.2) 0.21 LBM (kg) Median (IQR) 42.0 (37.1-50.6) 51.44 (5.6) 38.59 (6.9) <0.01 45.1 (8.9) 42.7 (8.9) 0.01 LSMI cm 2 /m 2 (median, IQR) 41.6 (35.43-45.98) n.a. n.a. 42.4 (8.3) 39.7 (7.6) <0.01 Cisplatin dose-limiting toxicity Of the 343 included patients, 154 patients (44.9%) experienced cisplatin DLT. Fig. 1 shows a boxplot of the amount of SMM expressed as LSMI (cm 2 /m 2 ) in patients who have not experi - enced cisplatin DLT and patients who experienced cisplatin DLT. Table 3 shows the types of cisplatin DLT categorized into patients with low SMM and without low SMM. Of the 154 patients that experienced DLT, in 145 patients (94.2%) this was due to the failure to complete all (n=3) cycles of cisplatin, in 6 patients (3.9%) this was due to a treatment delay of ≥ 4 days and in 3 patients this was due to a cisplatin de-escalation of ≥ 50% (1.9%). The causes of cisplatin DLT were ototoxicity (n= 64, 41.6%), nephrotoxicity (n=41, 26.6%), malaise (n=29, 18.8%), he - matopoietic toxicity (n=12, 7.8%), vascular toxicity (n=6, 3.9%) and neurotoxicity (n=1, 0.6%). 10